TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8484622

Group type: EXPERIMENTAL
Intervention: Max‐EPA (3.2 g/day eicosapentaenoic acid)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 37
Study: 3554063

Group type: EXPERIMENTAL
Intervention: Lamicel
Number of subjects: 219

Group type: COMPARATOR
Intervention: Multiple laminaria
Number of subjects: 219
Study: 29449506

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) 40 mg subcutaneously every other week for 6 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 49
Study: 26910749

Group type: EXPERIMENTAL
Intervention: Progesterone supplementation following ART (dydrogesterone)
Number of subjects: 1140

Group type: COMPARATOR
Intervention: No progesterone supplementation (control group)
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: Dydrogesterone only
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: Combination of dydrogesterone and hydroxyprogesterone caproate
Number of subjects: 1140
Study: 24924427

Group type: EXPERIMENTAL
Intervention: Intermediate pressure distribution models
Number of subjects: 0

Group type: COMPARATOR
Intervention: Over-concentrated pressure distribution models
Number of subjects: 0

Group type: COMPARATOR
Intervention: Over-even pressure distribution models
Number of subjects: 0
Study: 22433581

Group type: EXPERIMENTAL
Intervention: Short-term (7 day) urethral catheterization
Number of subjects: 512

Group type: COMPARATOR
Intervention: Longer-term (14 day) urethral catheterization
Number of subjects: 512
Study: 21246845

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment based on syndrome differentiation, using Ashi points and specific acupuncture points (Yanglingquan, Taichong, Zusanli)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Muscular injection of Bucinnazine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medication (Bucinnazine)
Number of subjects: 100
Study: 18441320

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg > 6 h before CAG (group A)
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Clopidogrel 600 mg in the cath-lab after CAG only in case of PCI (group B)
Number of subjects: 1028
Study: 11160558

Group type: EXPERIMENTAL
Intervention: Low fat, high carbohydrate diet (< or =24% fat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low fat diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progressive reduction of dietary fat with isocaloric substitution of carbohydrate
Number of subjects: 0
Study: 9734550

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) for 50 weeks
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) for 38 weeks and then 12 weeks of placebo
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) for 14 weeks and then 36 weeks of placebo
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo for 50 weeks
Number of subjects: 395
Study: 7925206

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.75 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intubation conditions assessed at 45 s
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intubation conditions assessed at 60 s
Number of subjects: 60
Study: 3287909

Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg for two days
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg for five days
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg four times per day
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg for one day
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 31380560

Group type: EXPERIMENTAL
Intervention: Iron status (measured by various biomarkers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iron status (liberal approach)
Number of subjects: 0
Study: 29188889

Group type: EXPERIMENTAL
Intervention: Vitamin B12 intake (assessed in a subsample)
Number of subjects: 2919

Group type: EXPERIMENTAL
Intervention: Vitamin B12 intake
Number of subjects: 2919

Group type: EXPERIMENTAL
Intervention: Vitamin B12 levels
Number of subjects: 2919

Group type: EXPERIMENTAL
Intervention: HoloTC levels
Number of subjects: 2919

Group type: EXPERIMENTAL
Intervention: Vitamin B12 and HoloTC levels
Number of subjects: 2919
Study: 26180220

Group type: EXPERIMENTAL
Intervention: Videoconference educational outreach
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person educational outreach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study: 23446895

Group type: EXPERIMENTAL
Intervention: Plasma TFAs
Number of subjects: 305
Study: 20822942

Group type: EXPERIMENTAL
Intervention: Real rTMS targeting the right secondary somatosensory cortex (SII) for 10 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real rTMS targeting the right secondary somatosensory cortex (SII)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham rTMS (control group)
Number of subjects: 0
Study: 18810233

Group type: EXPERIMENTAL
Intervention: Very Early Mobilisation (VEM)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 71
Study: 16571878

Group type: EXPERIMENTAL
Intervention: 90 microg subvirion influenza A (H5N1) vaccine
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: 45 microg subvirion influenza A (H5N1) vaccine
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: 15 microg subvirion influenza A (H5N1) vaccine
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: 7.5 microg subvirion influenza A (H5N1) vaccine
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study: 12752833

Group type: EXPERIMENTAL
Intervention: PENS plus PT
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham PENS plus PT
Number of subjects: 34
Study: 10681608

Group type: EXPERIMENTAL
Intervention: Calcipotriol cream (50 microg/g) combined with twice weekly broad-band UVB
Number of subjects: 0
Study: 9080870

Group type: EXPERIMENTAL
Intervention: Chloroquine (5 mg base/kg, n = 20)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Primaquine (0.5 mg base/kg, n = 30)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (n = 41)
Number of subjects: 91
Study: 8442748

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behaviour Therapy
Number of subjects: 0
Study: 30783724

Group type: EXPERIMENTAL
Intervention: Joint tip graft
Number of subjects: 30

Group type: COMPARATOR
Intervention: Joint tip graft not used (Control)
Number of subjects: 30
Study: 29148904

Group type: EXPERIMENTAL
Intervention: Without watertight duraplasty (test group)
Number of subjects: 58

Group type: COMPARATOR
Intervention: With watertight duraplasty (control group)
Number of subjects: 58
Study: 26901534

Group type: EXPERIMENTAL
Intervention: AFO-ON
Number of subjects: 11

Group type: COMPARATOR
Intervention: AFO-OFF
Number of subjects: 11
Study: 25268505

Group type: EXPERIMENTAL
Intervention: Interval walking training (IWT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (CNT)
Number of subjects: 28
Study: 22333328

Group type: EXPERIMENTAL
Intervention: Naltrexone (oral, Revia)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 20% alcohol availability
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 80% alcohol availability
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Locked trials during 80% availability
Number of subjects: 58
Study: 20738437

Group type: EXPERIMENTAL
Intervention: Moderate‐intensity or more‐vigorous physical activity (MVPA)
Number of subjects: 424
Study: 18600342

Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel Group (HS-G)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Clip-Ligation Group (CL-G)
Number of subjects: 76
Study: 16928842

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg tablets given twice daily
Number of subjects: 199

Group type: COMPARATOR
Intervention: Clarithromycin 500 mg extended-release tablets given once daily
Number of subjects: 199
Study: 14605279

Group type: EXPERIMENTAL
Intervention: HP-HF (high permeability haemofiltration)
Number of subjects: 28

Group type: COMPARATOR
Intervention: C-HF (conventional haemofiltration)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: HP ultrafiltrates
Number of subjects: 28

Group type: COMPARATOR
Intervention: C ultrafiltrates
Number of subjects: 28
Study: 11008045

Group type: EXPERIMENTAL
Intervention: MemoryLens
Number of subjects: 50

Group type: COMPARATOR
Intervention: AcrySof
Number of subjects: 50
Study: 8708224

Group type: EXPERIMENTAL
Intervention: Positioning with the unaffected lung down
Number of subjects: 39

Group type: COMPARATOR
Intervention: Positioning with the affected lung down
Number of subjects: 39

Group type: COMPARATOR
Intervention: Semi-Fowler's position
Number of subjects: 39
Study: 1432551

Group type: EXPERIMENTAL
Intervention: Acoustic stimulation test (n = 62)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Oxytocin challenge test only (n = 59)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Oxytocin challenge test (n = 121)
Number of subjects: 121
Study: 4064917

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cimetidine 600 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30807328

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral Sucrose
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study: 29995062

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combined Therapy (CT)
Number of subjects: 51
Study: 26874258

Group type: EXPERIMENTAL
Intervention: Neostigmine 40 μg.kg(‐1)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Neostigmine 0 μg.kg(‐1)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Neostigmine 10 μg.kg(‐1)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Neostigmine 20 μg.kg(‐1)
Number of subjects: 112
Study: 24842862

Group type: EXPERIMENTAL
Intervention: Improved unilateral recession-resection (R&R)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Unilateral medial rectus resection (UMR)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Bilateral medial rectus resections (BMR)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All surgical procedures (UMR, BMR, R&R)
Number of subjects: 45
Study: 22227912

Group type: EXPERIMENTAL
Intervention: Reusable SCLs
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Extended Wear (EW) lenses
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Age (per year older)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Silicone Hydrogel (SiHy)
Number of subjects: 166
Study: 19342014

Group type: EXPERIMENTAL
Intervention: SonoAVC (automated measurement of follicle diameter)
Number of subjects: 72

Group type: COMPARATOR
Intervention: 2D ultrasound (conventional measurement of follicle diameter)
Number of subjects: 72
Study: 17427539

Group type: EXPERIMENTAL
Intervention: Ligation of intersphincteric fistula tract (LIFT) technique
Number of subjects: 18
Study: 15766427

Group type: EXPERIMENTAL
Intervention: Computerized angle measurement software at a digital workstation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standardized technique using a film marker and goniometer on plain film
Number of subjects: 25
Study: 12063831

Group type: EXPERIMENTAL
Intervention: Combination of 5‐FU and radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine in chemoradiotherapy regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative therapy
Number of subjects: 0
Study: 9627274

Group type: EXPERIMENTAL
Intervention: Enalaprilat (0.5 mg bolus followed by incremental infusion up to 10 mg, mean 8.3 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no enalaprilat)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Enalaprilat
Number of subjects: 16

Group type: COMPARATOR
Intervention: Enalaprilat and Control
Number of subjects: 16
Study: 8583442

Group type: EXPERIMENTAL
Intervention: Opsite skin closure
Number of subjects: 99

Group type: COMPARATOR
Intervention: Subcuticular Vicryl
Number of subjects: 99
Study: 2231061

Group type: EXPERIMENTAL
Intervention: Screening for colorectal cancer; no specific intervention details provided.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer; no specific intervention details provided.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for skin cancer; no specific intervention details provided.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for oral cancer; no specific intervention details provided.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for testicular cancer; no specific intervention details provided.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical-examination cancer-screening procedure; no specific intervention details provided.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized screening trials funded by NCI; no specific intervention details provided.
Number of subjects: 0
Study: 362197

Group type: EXPERIMENTAL
Intervention: 10‐mg clotrimazole buccal troches taken five times daily for two weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo taken five times daily for two weeks
Number of subjects: 20
Study: 30958973

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.1 g·kg‐1·day‐1 of creatine + 0.1 g·kg‐1·day‐1 of maltodextrin) during 8 weeks of HVRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-velocity resistance training (HVRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0.2 g·kg‐1·day‐1 of maltodextrin) during 8 weeks of HVRT
Number of subjects: 0
Study: 28636579

Group type: EXPERIMENTAL
Intervention: Regeneration group
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Resistance group
Number of subjects: 130

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 130
Study: 26255520

Group type: EXPERIMENTAL
Intervention: Acupuncture at Zhibian (BL 54) through Shuidao (ST 28)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Regular acupuncture technique
Number of subjects: 101
Study: 23334268

Group type: EXPERIMENTAL
Intervention: Local administration of piperacillin/tazobactam
Number of subjects: 36

Group type: COMPARATOR
Intervention: Debridement alone
Number of subjects: 36
Study: 22152494

Group type: EXPERIMENTAL
Intervention: F-YOP (yoghurt pack)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control
Number of subjects: 3
Study: 19437211

Group type: EXPERIMENTAL
Intervention: Tomato sauce meal (tomato sauce, rice and olive oil)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo meal (rice and olive oil)
Number of subjects: 10
Study: 16428532

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 38
Study: 14760442

Group type: EXPERIMENTAL
Intervention: Barium swallow approach for determining septal puncture site
Number of subjects: 84

Group type: COMPARATOR
Intervention: Normal fluoroscopic view for determining septal puncture site
Number of subjects: 84
Study: 10768702

Group type: EXPERIMENTAL
Intervention: Contingent vouchers for opiate-negative urine specimens (n = 29 patients)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Methadone hydrochloride dose increase to 70 mg/d (n = 31 patients)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined contingent vouchers and methadone dose increase (n = 32 patients)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Neither intervention (comparison standard; n = 28 patients)
Number of subjects: 120
Study: 8808718

Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg once daily for 15 days
Number of subjects: 294

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily for 15 days
Number of subjects: 294
Study: 1425877

Group type: EXPERIMENTAL
Intervention: nalbuphine (0.2 mg.kg‐1 i.v.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 4016785

Group type: EXPERIMENTAL
Intervention: Low-dose treatment strategy (2 X 10(6) units/m2 daily for 28 days, then daily for 5 days every other week by im injection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose treatment strategy (5 X 10(6) units/m2 by continuous iv infusion over 24 hours, escalating by 5 X 10(6) units/m2/day as tolerated over 10 days, repeated every 28 days)
Number of subjects: 0
Study: 30927922

Group type: EXPERIMENTAL
Intervention: Fastrach
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ambu Aura‐i
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 80
Study: 31156013

Group type: EXPERIMENTAL
Intervention: Seizure action plan + standard care
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 102
Study: 27796466

Group type: EXPERIMENTAL
Intervention: Netazepide 1 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Netazepide 5 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Netazepide 25 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg daily for 28 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 25997746

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Different TNFi
Number of subjects: 139
Study: 23446906

Group type: EXPERIMENTAL
Intervention: High-protein (HP) breakfast (350-kcal, 35 g protein)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Normal-protein (NP) breakfast (350-kcal, 13 g protein)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Breakfast skipping (BS)
Number of subjects: 20
Study: 21794128

Group type: COMPARATOR
Intervention: Attention Network Test (ANT)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Attention Network Test (ANT) in ADHD subgroup with affective fluctuations (n = 22)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Attention Network Test (ANT) in ADHD subgroup without affective fluctuations
Number of subjects: 114
Study: 19326695

Group type: EXPERIMENTAL
Intervention: SPF 40 sunscreen cream containing ecamsule 3%, octocrylene 10%, avobenzone 2%, and titanium dioxide 5% (tetrad)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Ecamsule-deprived cream (triad-E)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Avobenzone-deprived cream (triad-A)
Number of subjects: 144
Study: 16957433

Group type: EXPERIMENTAL
Intervention: Topical retapamulin ointment, 1% for 5 days twice daily
Number of subjects: 1904

Group type: COMPARATOR
Intervention: Oral cephalexin, 500 mg twice daily for 10 days
Number of subjects: 1904
Study: 15016485

Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily
Number of subjects: 20536
Study: 11703421

Group type: EXPERIMENTAL
Intervention: Metformin (MG)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (PG)
Number of subjects: 26
Study: 9155314

Group type: EXPERIMENTAL
Intervention: Contingency contracting intervention with nurses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High levels of adherence to nutrition recommendations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low levels of adherence to nutrition recommendations
Number of subjects: 0
Study: 7536071

Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (LD-CY, 1500 mg/m2) plus cisplatin (CDDP) 100 mg/m2 (OvCa) or epirubicin (EPR) 120 mg/m2 (BrCa) plus recombinant human G-CSF (rhG-CSF)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC) with carboplatin 1200 mg/m2, etoposide 900 mg/m2 and melphalan 100 mg/m2 with reinfusion of PBSC
Number of subjects: 12
Study: 3148298

Group type: EXPERIMENTAL
Intervention: Oral administration of human milk since the 15th day of TPN
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral metronidazole since the 15th day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Parenteral antibiotic therapy for septicemia since the 1st day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 28736267

Group type: EXPERIMENTAL
Intervention: Gamma tocopherol (γT) 1200 mg daily for 14 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 27591457

Group type: EXPERIMENTAL
Intervention: Active warming from a thermal gown 30min before spinal anesthesia and during surgery (Go, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No active warming at any time (Ct, n=20)
Number of subjects: 40
Study: 24712568

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 3 mg T enanthate
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 6.25 mg T enanthate
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 12.5 mg T enanthate
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 25 mg T enanthate
Number of subjects: 71
Study: 24060060

Group type: EXPERIMENTAL
Intervention: Incredible Years Teacher Classroom Management (IY-TCM) program
Number of subjects: 107
Study: 21518073

Group type: EXPERIMENTAL
Intervention: Experimental group (n=85) received an educational session, dental supplies, and scheduled oral care appointment.
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (n=85) did not receive the intervention.
Number of subjects: 170
Study: 18442447

Group type: EXPERIMENTAL
Intervention: Grouped dot displays
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Dispersed dot displays
Number of subjects: 140
Study: 16832795

Group type: EXPERIMENTAL
Intervention: Personalized telephone counseling and individually tailored materials, including motivational goal-setting session, three sets of tailored materials, three follow-up counseling sessions, and linkages to free screening programs.
Number of subjects: 494

Group type: COMPARATOR
Intervention: Usual care arm, which included physician suggestion to notify family members about melanoma diagnosis and encourage screening.
Number of subjects: 494